Table 4.

IFN-γ T-cell responses, autoimmune toxicities and clinical outcomes by patient and in aggregate

Patient	Study arm	Vaccine with:		T-cell response detected to:			Baseline* ANA/RF+	On-treatment ANA+	Melanoma clinical outcome October 2019
		pBCAR3	pIRS2	pBCAR3	pIRS2	Either			Recurrence	Died
1	A	+						+	+	+
2	A	+
3	B		+					+	+
4	A	+		+		+		+	+
5	B		+		+	+			+	+
6	B		+						+
7	C	+	+				+
8	C	+	+	+	+	+			+
9	C	+	+						+
10	C	+	+				+		+
11	C	+	+		+	+			+
12	C	+	+
13	C	+	+		+	+			+	+
14	C	+	+
15	C	+	+		+	+	+
Total		12	12	2	5	6	3	3	10	3
# vaccinated with that peptide				12	12	15
% T-cell response to peptide				17%	42%	40%
90% CI T-cell responses				3% to 44%	18% to 68%	19% to 64%

ANA, antinuclear antibody; IFN-γ, interferon-γ; pBCAR3, phosphopeptide from breast cancer antiestrogen resistance 3; pIRS2, phosphopeptide from insulin receptor substrate 2; RF, rheumatoid factor.